US20210308026A1 - Topical compositions for reducing the effects of aging - Google Patents
Topical compositions for reducing the effects of aging Download PDFInfo
- Publication number
- US20210308026A1 US20210308026A1 US17/143,428 US202117143428A US2021308026A1 US 20210308026 A1 US20210308026 A1 US 20210308026A1 US 202117143428 A US202117143428 A US 202117143428A US 2021308026 A1 US2021308026 A1 US 2021308026A1
- Authority
- US
- United States
- Prior art keywords
- composition
- pemulen
- skin
- topical
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 230000000694 effects Effects 0.000 title claims abstract description 19
- 230000032683 aging Effects 0.000 title claims abstract description 7
- 230000000699 topical effect Effects 0.000 title claims description 24
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical group C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229950010130 tamibarotene Drugs 0.000 claims abstract description 51
- 239000004251 Ammonium lactate Substances 0.000 claims abstract description 39
- 229940059265 ammonium lactate Drugs 0.000 claims abstract description 39
- 235000019286 ammonium lactate Nutrition 0.000 claims abstract description 39
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims abstract description 39
- 238000009472 formulation Methods 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 26
- 239000003995 emulsifying agent Substances 0.000 claims description 23
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 20
- 229920006037 cross link polymer Polymers 0.000 claims description 20
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 18
- 239000007764 o/w emulsion Substances 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 13
- 239000002085 irritant Substances 0.000 claims description 12
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 11
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 9
- 230000037303 wrinkles Effects 0.000 claims description 9
- 206010040954 Skin wrinkling Diseases 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000034656 Contusions Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010040799 Skin atrophy Diseases 0.000 claims description 3
- 206010040829 Skin discolouration Diseases 0.000 claims description 3
- 206010040851 Skin fragility Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 230000037370 skin discoloration Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 238000013019 agitation Methods 0.000 description 39
- 210000003491 skin Anatomy 0.000 description 34
- 238000003756 stirring Methods 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 26
- 239000000839 emulsion Substances 0.000 description 25
- 239000003921 oil Substances 0.000 description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 22
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 16
- 239000002537 cosmetic Substances 0.000 description 15
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 15
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 15
- 244000194101 Ginkgo biloba Species 0.000 description 14
- 239000003205 fragrance Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000006096 absorbing agent Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940008099 dimethicone Drugs 0.000 description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 description 11
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 11
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 11
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 11
- 229960002216 methylparaben Drugs 0.000 description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 11
- 229960003415 propylparaben Drugs 0.000 description 11
- 235000019271 petrolatum Nutrition 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 238000004945 emulsification Methods 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000003871 white petrolatum Substances 0.000 description 9
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 8
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 8
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 8
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 8
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000516 sunscreening agent Substances 0.000 description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 5
- 238000007667 floating Methods 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 235000011201 Ginkgo Nutrition 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- -1 bisabalol Substances 0.000 description 3
- 229940036350 bisabolol Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008271 cosmetic emulsion Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000008309 hydrophilic cream Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- 239000004907 Macro-emulsion Substances 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 231100000159 OECD 404 Acute Dermal Irritation/Corrosion Toxicity 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- VLRYIIPJIVGFIV-QQSFYHFXSA-N maniladiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C VLRYIIPJIVGFIV-QQSFYHFXSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- 0 *OC(=O)C(C)(C)CC(CC)C(=O)O Chemical compound *OC(=O)C(C)(C)CC(CC)C(=O)O 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- JMHSCWJIDIKGNZ-UHFFFAOYSA-N 4-carbamoylbenzoic acid Chemical compound NC(=O)C1=CC=C(C(O)=O)C=C1 JMHSCWJIDIKGNZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000034356 Aframomum angustifolium Species 0.000 description 1
- 235000010166 Aframomum angustifolium Nutrition 0.000 description 1
- RIPVHYXJSKFKMM-UHFFFAOYSA-N CC(=O)NC1=CC2=C(C=C1)C(C)(C)CCC2(C)C.CC(=O)NC1=CC=CC=C1.CC(C)(Cl)CCC(C)(C)Cl.CC(C)(O)CCC(C)(C)O.CC1(C)CCC(C)(C)C2=C1C=CC(CC(=O)C1=CC=C(C(=O)O)C=C1)=C2.CC1(C)CCC(C)(C)C2=C1C=CC(N)=C2.COC(=O)C1=CC=C(C(=O)CC2=CC3=C(C=C2)C(C)(C)CCC3(C)C)C=C1.COC(=O)C1=CC=C(ClC=O)C=C1.Cl.[N-]=[N+]=NO.[N-]=[N+]=NO Chemical compound CC(=O)NC1=CC2=C(C=C1)C(C)(C)CCC2(C)C.CC(=O)NC1=CC=CC=C1.CC(C)(Cl)CCC(C)(C)Cl.CC(C)(O)CCC(C)(C)O.CC1(C)CCC(C)(C)C2=C1C=CC(CC(=O)C1=CC=C(C(=O)O)C=C1)=C2.CC1(C)CCC(C)(C)C2=C1C=CC(N)=C2.COC(=O)C1=CC=C(C(=O)CC2=CC3=C(C=C2)C(C)(C)CCC3(C)C)C=C1.COC(=O)C1=CC=C(ClC=O)C=C1.Cl.[N-]=[N+]=NO.[N-]=[N+]=NO RIPVHYXJSKFKMM-UHFFFAOYSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 101001099854 Xenopus laevis Cellular retinoic acid-binding protein 2 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 150000003436 stilbenoids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Definitions
- the present invention relates to novel cosmetic, and pharmaceutical compositions containing tamibarotene or ammonium lactate for topical application in the treatment of wrinkles and dry skin.
- Cosmetic preparations are widely used to improve looks or the way a person feels about themselves. To be successful products must deliver visible results without side effects and should appear natural. Various retinoids are known for their antiaging properties
- Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta.
- Tamibarotene is orally active and was developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.
- ATRA all-trans retinoic acid
- tamibarotene Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials. Miwako I, Kagechika H R&R Inc., Tokyo, Japan. Drugs of Today (Barcelona, Spain: 1998) [2007, 43(8):563-568]. The structure of tamibarotene is shown below.
- Tamibarotene may be synthesized as follows:
- Formulation of retinoids for topical delivery is problematic in that the formulations are unstable and rapidly degrade.
- Ammonium lactate is a moisturizing agent known in the art that is typically formulated as an oil in water emulsion for topical administration.
- sufactants used to emulsify sunscreen agents also remove the agents used to promote absorption from the skin when in the presence of water. This causes loss of UV absorbent activity and sun protectant effects sunscreen agents is lost.
- the present ammonium lactate formulation solves the problem by using a new emulsification technology based on Pemulen.
- This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium, in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (PemulenTM TR-1 Polymeric Emulsifier).
- the Acrylates/C10-30 Alkyl Acrylate Crosspolymer is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11.
- Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin.
- creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%.
- Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted
- This invention provides novel topical cosmeceutical combinations of compositions of tamibarotene, a natural and synthetic phytochemical and salts with ammonium lactate, bisabalol, polyvinyl pyrrolidone (PVP K15 to K90) for improvement of skin appearance in normal and aged human skin.
- PVP K15 to K90 polyvinyl pyrrolidone
- the present formulations are stable for tamibarotene and the formulation itself.
- the tamibarotne is dissolved in a polyethylene glycol (PEG) such as PEG 300 which is liquid at room temperature.
- PEG polyethylene glycol
- the formulation comprises a compositions which is waxy at room temperature such as polyethylene glycol 1540.
- the formulation also contains light mineral oil, glyceryl stearate, PEG-100 stearate, propylene glycol, polyoxyl 40 stearate, glycerin, magnesium aluminum silicate, laureth-4, cetyl alcohol, methyl and propyl parabens, methylcellulose, fragrance and water.
- tamibarotene is formulated with 0.05-15 percent lactic acid neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.0-6.0 suitable for use on the skin.
- sunscreens may be part of the formulation.
- the formulation comprises antioxidants such as butylated hydroxytoluene (“BHT”) or vitamin E.
- BHT butylated hydroxytoluene
- vitamin E vitamin E
- Tamibarotene and salts thereof can be combined in binary and ternary composition with other phytochemical cosmetic anti-aging agents such as Rosmarinus officinalis, specifically carnosic acid, Vitis vinifera (grape seed extract), specifically V. vinifera contains many phenolic compounds.
- Anthocyanins can be found in the skin of the berries, hydroxycinnamic acids in the pulp and condensed tannins of the proanthocyanidins type in the seeds.
- Stilbenoids can be found in the skin and in wood.
- Citronellol Citronellol
- limonene fruit acids
- Oenothera biennis evening primrose oil, which is used for skin disorders such as eczema, psoriasis, and acne).
- Glycyrrhiza glabra (licorice extract), Aframomum angustifolium seed extract, Diosgenin (wild yam), N6 furfuryladenine(kinetin), and Ergothioneine. These treatments are particularly effective on persons afflicted by stress induced lines and wrinkles and reduction of acne lesions and to improve skin texture and skin color without an increase in puffiness
- tamibarotene 0.05 to 15 percent
- an anti-irritant on a daily basis is effective to reduce deep wrinkles.
- tamibarotene (0.05 to 15 percent) formulated as in Example 1 topically to the skin enhances the skin image and reduce the wrinkles for a period from about 8 to about 14 hours.
- An embodiment of the present invention solves the problem by using a new emulsification technology based on Pemulen.
- This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium-(1), in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (PemulenTM TR-1 Polymeric Emulsifier).
- the Acrylates/C10-30 Alkyl Acrylate Crosspolymer is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11.
- Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin.
- creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%.
- Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted by water.
- Pemulen TR1 is a polymeric emulsifier produced by Noveon.
- Pemulen TR-1 is part of a class of copolymers arc referred to as acrylate/C10-30 alkyl acrylate cross polymers (6), having the following structure: See http://pemulentr2.pbworks.com/f/PemulenTR2.pdf
- Pemulen TR1 or TR2 can act as a primary emulsifier, that is, it can be used to make oil in water emulsions without the usual required addition of soap or surfactant.
- Pemulen TR1 or TR2 does not form emulsions in the same way that traditional surfactants do.
- a traditional surfactant surrounds a droplet of oil to keep it suspended in oil.
- Pemulen TR1 is said to form stable O/W emulsions with as little as 0.4%, binding to the oil droplets with the lipophilic portions of the polymer chain that forms the gel.
- Pemulen TR-1 Gels made with Pemulen TR-1 are most viscous in the pH range of 5-9. A range of alkaline materials are suggested by the manufacturer to formulate aqueous gels using Pemulen TR-1, including sodium hydroxide, ammonium hydroxide, triethanolamine (TEA), and Ethameen C-25.
- Pemulen is designed to break when the gel is in contact with a salt concentration similar to what one would find on human skin. This is a desirable in the cosmetics industry where moisturizers need to be quickly delivered and absorbed into the user's skin, but this may be a less desirable characteristic of an emulsion designed to clean works of art. In practice, this breakage of the emulsion has been observed when attempting to clean very grimy areas and allowing the gel to dwell for an extended period. Although the vast majority of cream or emulsion products in the marketplace contain water-insoluble actives, the surfactants can re-emulsify the actives and cause wash-off, leaving the skin unprotected.
- This invention specially formulates tamibarotene to provide a cream pH of 4.5-6.5. It may also contain glycerin, isopropyl palmitate, dimethicone, ginko biloba, methyl paraben, propyl paraben or butyl parabens fragrance and water.
- Tamibarotene is present from about 0.05-15 percent.
- the formulation comprises alpha-Bisabolol, an anti-irritant, and/or a retinoid, such as Tamibarotene. or a triterpinoid such as Betulen [473-98-3] C30H50O2, molecular mass 442,7 and related compounds like betulin, lupeol, and betulinic acid.
- the formula is a ternary formulation consisting of three parts which are ultimately combined to form a stable oil in water emulsion.
- the order of addition of the ingredients should be followed strictly as written. Otherwise, the ingredients fall out of solution.
- Part 1 is formed as follows:
- Part 2 is formed as follows:
- the final formulation is produced as follows:
- a tamibarotene cream was prepared by conventional methods according to the following formulation (data in % by weight) in Table 3.
- OECD 404 Organization for Economic Co-Operation and Development (OECD), Guidelines for the Testing of Chemicals, “Acute Dermal Irritation/Corrosion”, adopted 24 Apr. 2002.
- the skin of three albino rabbits was prepared for testing by clipping the skin of the trunk free of hair at the application sites within 24 hours of the test.
- the sites of application were not abraded deliberately or accidentally during preparation.
- Tamibarotene was administered at dose levels of 0.02%, 0.04%, and 0.08% in 60% DMSO.
- the animals were treated by introducing each dose level (0.5 ml) under gauze patches at individual application sites.
- the control 0.5 ml of 60% DMSO was applied to a fourth site.
- test article was tested for its potential to produce primary dermal irritation after a single topical 4-hour application to the skin of albino rabbits.
- the test article was considered a non-irritant when tested at dose levels of 0.02%, 0.04%, and 0.08% in 60% DMSO.
- Ammonium lactate is a moisturizing agent known in the art that is typically formulated as an oil in water emulsion for topical administration.
- sufactants used to emulsify sunscreen agents also remove the agents used to promote absorption from the skin when in the presence of water. This causes loss of UV absorbent activity and sun protectant effects sunscreen agents is lost.
- the present invention solves the problem by using a new emulsification technology based on Pemulen.
- This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium-(1), in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (PemulenTM TR-1 Polymeric Emulsifier).
- the Acrylates/C10-30 Alkyl Acrylate Crosspolymer is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11.
- Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin.
- creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%.
- Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted by water.
- Pemulen TR1 is a polymeric emulsifier produced by Noveon.
- Pemulen TR-1 is part of a class of copolymers are referred to as acrylate/C10-30 alkyl acrylate cross polymers (6), having the following structure:
- Pemulen TR1 or TR2 can act as a primary emulsifier, that is, it can be used to make oil in water emulsions without the usual required addition of soap or surfactant.
- Pemulen TR1 or TR2 docs not form emulsions in the same way that traditional surfactants do.
- a traditional surfactant surrounds a droplet of oil to keep it suspended in oil.
- Pemulen TR1 is said to form stable O/W emulsions with as little as 0.4%, binding to the oil droplets with the lipophilic portions of the polymer chain that forms the gel.
- Pemulen TR-1 Gels made with Pemulen TR-1 are most viscous in the pH range of 5-9. A range of alkaline materials are suggested by the manufacturer to formulate aqueous gels using Pemulen TR-1, including sodium hydroxide, ammonium hydroxide, triethanolamine (TEA), and Ethameen C-25.
- Pemulen is designed to break when the gel is in contact with a salt concentration similar to what one would find on human skin. This is a desirable in the cosmetics industry where moisturizers need to be quickly delivered and absorbed into the user's skin, but this may be a less desirable characteristic of an emulsion designed to clean works of art. In practice, this breakage of the emulsion has been observed when attempting to clean very grimy areas and allowing the gel to dwell for an extended period. Although the vast majority of cream or emulsion products in the marketplace contain water-insoluble actives, the surfactants can re-emulsify the actives and cause wash-off, leaving the skin unprotected.
- Ammonium lactate is the ammonium salt of lactic acid. This product specially formulates ammonium lactate 20 wt. percent to provide a cream pH of 4.5-6.5. It may also contain glycerin, isopropyl palmitate, dimethicone, ginko biloba, methyl paraben, propyl paraben or butyl parabens fragrance and water.
- the percentage of Ammonium lactate is preferably between about 17 to about 20 percent.
- the formulation comprises alpha-Bisabolol, an anti-irritant, and/or a retinoid, such as Tamibarotene, or a triterpinoid such as Betulen [473-98-3] C30H50O2, molecular mass 442,7 and related compounds like betulin, lupeol, and betulinic acid.
- the formula is a ternary formulation consisting of three parts which are ultimately combined to form a stable oil in water emulsion.
- the order of addition of the ingredients should be followed strictly as written in Table 4 and the description that follows. Otherwise, the ingredients fall out of solution.
- Part 1 is formed as follows:
- Part 2 is formed as follows:
- the final formulation is produced as follows:
- a combination tamibarotene and ammonium lactate anti-wrinkle emulsion can be prepared as shown below.
- Ginkgo Ginkgo biloba 1.0 5.0 Total 25.0 125.0 Ternary Ingredients-Part 3 Order of Addition 1.
- Pemulen ® TR 1.5 7.5 2.
- Fragrance Belle Air #7564 0.2
- a composition for reducing the effects of aging comprising tamibarotene in a cosmetically acceptable carrier.
- the effects of aging are selected from increase in skin roughness, loss of skin elasticity, increase in skin transparency, skin fragility, increased frequency of bruising, macroscopic appearance of skin wrinkles and folds, and skin discoloration.
- the carrier is at least one polyethylene glycol (PEG) of cosmetically acceptable grade.
- the polyethylene glycol is a mixture of PEG 300 and PEG 1540.
- the tamibarotene is dissolved in PEG 300 and added to melted PEG 1540.
- the composition further comprises an anti-irritant.
- the anti-irritant is (-)- ⁇ -Bisabolol.
- the composition comprises an antioxidant.
- the anti-oxidant is butylated hydroxytoluene (BHT).
- BHT butylated hydroxytoluene
- the composition is stable at room temperature.
- the topical formulation is a formulation that is a sterically stabilized oil in water (o/w) emulsion.
- the ammonium lactate is present from about 17 to about 20 percent by weight, in another embodiment, the composition further comprises an anti-irritant and/or a retinoid.
- the anti-irritant is (-)- ⁇ -Bisabolol.
- tamibarotene comprising:
- the ternary formulation comprises an additional cosmetic agent.
- the ternary formulation is a formulation in which:
- tamibarotene In another aspect of the invention is a method of making a ternary formulation of tamibarotene comprising:
- the topical formulation in another embodiment is a topical formulation of ammonium lactate in an acrylates/C10-30 alkyl acrylate crosspolymer.
- the formulation is an oil in water (o/w) emulsion.
- the ammonium lactate is present from about 17 to about 20 percent by weight.
- the topical formulation comprises an anti-irritant, and or a retinoid.
- the anti-irritant is (-)- ⁇ -Bisabolol and the retinoid is tamibarotene.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 16/380,808, filed Apr. 10, 2019, which is a continuation of U.S. patent application Ser. No. 14/775,920, filed Sep. 14, 2015, which is a U.S. National Stage patent application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2014/030033, filed Mar. 15, 2014, which claims benefit under 35 USC § 119(e) of U.S. Provisional Patent Application No. 61/790,370, filed Mar. 15, 2013, and to U.S. Provisional Patent Application No. 61/789,701, filed Mar. 15, 2013, the contents of which are incorporated by reference in their entirety.
- The present invention relates to novel cosmetic, and pharmaceutical compositions containing tamibarotene or ammonium lactate for topical application in the treatment of wrinkles and dry skin.
- Cosmetic preparations are widely used to improve looks or the way a person feels about themselves. To be successful products must deliver visible results without side effects and should appear natural. Various retinoids are known for their antiaging properties
- Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta.
- Tamibarotene is orally active and was developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.
- Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials. Miwako I, Kagechika H R&R Inc., Tokyo, Japan. Drugs of Today (Barcelona, Spain: 1998) [2007, 43(8):563-568]. The structure of tamibarotene is shown below.
- Tamibarotene
- CAS No.: 94497-51-5
- Name: Benzoic acid, 4-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]-
- Superlist Name: Tamibarotene
- Formula: C22H25NO3
- Synonyms: 4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthalenyl)carbamoyl]benzoicacid;N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthyl)terephthalamic acid;Am 80 (pharmaceutical);Amnolake;NSC 608000;Retinoid. AM 80;
- Molecular Weight: 351.44
- Tamibarotene may be synthesized as follows:
- Formulation of cosmetics is well known in the art, United States published patent publication number 20110059892 to Phillippe Moussou provides examples of excipients widely use in cosmetic products.
- Formulation of retinoids for topical delivery is problematic in that the formulations are unstable and rapidly degrade.
- Ammonium lactate is a moisturizing agent known in the art that is typically formulated as an oil in water emulsion for topical administration. Currently available products suffer from the problem that sufactants used to emulsify sunscreen agents also remove the agents used to promote absorption from the skin when in the presence of water. This causes loss of UV absorbent activity and sun protectant effects sunscreen agents is lost.
- The present ammonium lactate formulation solves the problem by using a new emulsification technology based on Pemulen. This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium, in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (Pemulen™ TR-1 Polymeric Emulsifier). The Acrylates/C10-30 Alkyl Acrylate Crosspolymer, is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11. Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin. Like other oil in water cosmetic emulsions, creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%. Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted
- This invention provides novel topical cosmeceutical combinations of compositions of tamibarotene, a natural and synthetic phytochemical and salts with ammonium lactate, bisabalol, polyvinyl pyrrolidone (PVP K15 to K90) for improvement of skin appearance in normal and aged human skin.
- The present formulations are stable for tamibarotene and the formulation itself.
- In one embodiment the tamibarotne is dissolved in a polyethylene glycol (PEG) such as PEG 300 which is liquid at room temperature.
- In another embodiment the formulation comprises a compositions which is waxy at room temperature such as polyethylene glycol 1540.
- In some embodiments the formulation also contains light mineral oil, glyceryl stearate, PEG-100 stearate, propylene glycol, polyoxyl 40 stearate, glycerin, magnesium aluminum silicate, laureth-4, cetyl alcohol, methyl and propyl parabens, methylcellulose, fragrance and water.
- In other embodiments tamibarotene is formulated with 0.05-15 percent lactic acid neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.0-6.0 suitable for use on the skin.
- In another embodiment the formulation further comprises an anti-irritant such as bisabalol.
- In another embodiment, sunscreens may be part of the formulation.
- In yet another embodiment the formulation comprises antioxidants such as butylated hydroxytoluene (“BHT”) or vitamin E. BHT in higher concentrations may convey antiviral properties to the formulations herein.
- Tamibarotene and salts thereof, can be combined in binary and ternary composition with other phytochemical cosmetic anti-aging agents such as Rosmarinus officinalis, specifically carnosic acid, Vitis vinifera (grape seed extract), specifically V. vinifera contains many phenolic compounds. Anthocyanins can be found in the skin of the berries, hydroxycinnamic acids in the pulp and condensed tannins of the proanthocyanidins type in the seeds. Stilbenoids can be found in the skin and in wood.
- It can also be formulated with Citronellol, limonene, fruit acids, Oenothera biennis (evening primrose oil, which is used for skin disorders such as eczema, psoriasis, and acne).
- Glycyrrhiza glabra (licorice extract), Aframomum angustifolium seed extract, Diosgenin (wild yam), N6 furfuryladenine(kinetin), and Ergothioneine. These treatments are particularly effective on persons afflicted by stress induced lines and wrinkles and reduction of acne lesions and to improve skin texture and skin color without an increase in puffiness
- Application of tamibarotene (0.05 to 15 percent) alone or in a composition containing bisabalol, an anti-irritant on a daily basis is effective to reduce deep wrinkles.
- Method of Preparation
- 1. Calculate the required quantity of 0.05-15 percent of Tamibarotene (Molecular weight ˜450), and then calculate each ingredient for the total amount to be prepared 500 g.
- 2. Accurately weigh/measure each ingredient.
- 3. Dissolve the Tamibarotene and the butylated hydroxytoluene (BHT) in the polyethylene glycol 300.
- 4. Melt polyethylene glycol 1540 at about 55 C.
- 5. Add the Tamibarotene and BHT solution to the melted base, mix well and allow to cool.
- 6. Package and label.
- Application of tamibarotene (0.05 to 15 percent) formulated as in Example 1 topically to the skin enhances the skin image and reduce the wrinkles for a period from about 8 to about 14 hours.
- One of skill in the art will appreciate that considerable deviation from the teachings herein are permissible without departing from the spirit of the invention.
- Currently available cosmetic products suffer from the problem that sufactants used to emulsify sunscreen agents also remove the agents used to promote absorption from the skin when in the presence of water. This causes loss of UV absorbent activity and sun protectant effects sunscreen agents is lost.
- An embodiment of the present invention solves the problem by using a new emulsification technology based on Pemulen. This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium-(1), in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (Pemulen™ TR-1 Polymeric Emulsifier). The Acrylates/C10-30 Alkyl Acrylate Crosspolymer, is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11. Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin. Like other oil in water cosmetic emulsions, creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%. Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted by water.
- Pemulen TR1 is a polymeric emulsifier produced by Noveon. A block copolymer consisting of a poly acrylic acid similar to the Carbopol resins presently used to make aqueous and solvent gels in art conservation (Carbopol 934, Carbopol 940, Carbopol 941) cross-linked with a long-chained methacrylate, this carbomer has a lipohipllic regions (the methacrylate) as well as hydrophilic regions (the acrylic acid). In the cosmetic industry literature, Pemulen TR-1 is part of a class of copolymers arc referred to as acrylate/C10-30 alkyl acrylate cross polymers (6), having the following structure: See http://pemulentr2.pbworks.com/f/PemulenTR2.pdf
- These regions of differing affinity allow Pemulen TR1 or TR2 to act as a primary emulsifier, that is, it can be used to make oil in water emulsions without the usual required addition of soap or surfactant.
- Pemulen TR1 or TR2 does not form emulsions in the same way that traditional surfactants do. To produce oil in water emulsion, a traditional surfactant surrounds a droplet of oil to keep it suspended in oil. Nonionic surfactants used for cleaning painted surfaces, as described in Wolvers' Cleaning Painted Surfaces Aqueous Methods, might be used in concentrations as high as 30% to form a macroemulsion.
- In contrast, Pemulen TR1 is said to form stable O/W emulsions with as little as 0.4%, binding to the oil droplets with the lipophilic portions of the polymer chain that forms the gel.
- Gels made with Pemulen TR-1 are most viscous in the pH range of 5-9. A range of alkaline materials are suggested by the manufacturer to formulate aqueous gels using Pemulen TR-1, including sodium hydroxide, ammonium hydroxide, triethanolamine (TEA), and Ethameen C-25.
- One interesting feature possessed by Pemulen is that this emulsifying agent is designed to break when the gel is in contact with a salt concentration similar to what one would find on human skin. This is a desirable in the cosmetics industry where moisturizers need to be quickly delivered and absorbed into the user's skin, but this may be a less desirable characteristic of an emulsion designed to clean works of art. In practice, this breakage of the emulsion has been observed when attempting to clean very grimy areas and allowing the gel to dwell for an extended period. Although the vast majority of cream or emulsion products in the marketplace contain water-insoluble actives, the surfactants can re-emulsify the actives and cause wash-off, leaving the skin unprotected.
- Those familiar with the art have countered this phenomenon by incorporating waxes or water resistant, film-forming polymers into their formulations. Such a polymer forms an effective barrier, which prevents absorber wash-off, but it may produce negative aesthetic effects such as long rub-in times and a tacky or heavy feel on the skin. However, a novel combination of tamibarotene and Pemulen® polymeric emulsifiers meet the FDA definition of “water-proof” without the use of film-forming polymers, waxes and the like. Because these emulsions contain very little or no surfactants, the water-insoluble UV absorbers remain on the skin, even after an 80 minute exposure to water. The triggered release of the oil phase upon product application ensures that the absorbers are free to spread onto the epidermis where they are immediately active.
- This invention specially formulates tamibarotene to provide a cream pH of 4.5-6.5. It may also contain glycerin, isopropyl palmitate, dimethicone, ginko biloba, methyl paraben, propyl paraben or butyl parabens fragrance and water.
- In one embodiment Tamibarotene is present from about 0.05-15 percent. Optionally, the formulation comprises alpha-Bisabolol, an anti-irritant, and/or a retinoid, such as Tamibarotene. or a triterpinoid such as Betulen [473-98-3] C30H50O2, molecular mass 442,7 and related compounds like betulin, lupeol, and betulinic acid.
- The formula is a ternary formulation consisting of three parts which are ultimately combined to form a stable oil in water emulsion. The order of addition of the ingredients should be followed strictly as written. Otherwise, the ingredients fall out of solution.
-
TABLE 2 Ingredient Percent Weight (g) Ternary Ingredient-Part 1 Order of Addition Demineralized Water 63.1 155.5 Methyl Paraben 0.1 0.5 Propyl Paraben 0.1 0.5 Glycerin 2.0 10.0 Tamibarotene (20 wt. %) 8.0 200.0 Total 73.3 366.5 Ternary Ingredient-Part 2 Order of Addition Demineralized Water 18.0 90.0 Isopropyl Palmitate 2.5 12.5 Dimethicone (Mw 30,000) 2.5 12.5 White Petrolatum 1.0 5.0 Ginkgo (Ginkgo biloba) 1.0 5.0 Total 25.0 125.0 Ternary Ingredients-Part 3 Order of Addition Pemulen ® TR 1.5 7.5 Fragrance (Belle Air #7564) 0.2 1.0 Total 1.7 8.5 Total all 3 parts 100.0 500.0 - Part 1 is formed as follows:
-
- a. Add Demineralized water to a 1000 ml beaker. Stirring or Agitation at 600 rpm
- b. Add methyl paraben
- c. Add propyl paraben
- d. Add glycerin
- e. Add Tamibarotene
- f. Increase stirring rate or agitation to 1500 rpm
- Part 2 is formed as follows:
-
- a. Add demineralized water to an 800 ml beaker. Stir or Agitation at 600 rpm
- b. Add isopropyl palmitate
- c. Add dimethicone
- d. Add white petrolatum
- e. Add gingko biloba
- f. Increase agitation or stirring 1500 rpm
- Mix part 1 and part 2 for 30 minutes
-
- a. Slow agitation or stirring down on part 1 to 600 rpm and blend part 2 into part 1
- b. Increase agitation of the combined formulation to 1800 rpm for 30 minutes.
- The final formulation is produced as follows:
-
- a. Slow agitation of combined formulation to 600 rpm
- b. Add Pemulen® TR1 OR TR2 very slowly (all of it)
- c. Increase stirring speed to 1800 rpm for 30 minutes to disperse all of Pemulen® TR1 OR TR2
- d. Increase agitation to 2800 rpm and hold until the emulsion is smooth and creamy without any of the oils floating on the surface.
- e. Slow agitation down to 600 rpm and add the fragrance
- f. Mix well and place in a proper container (jar or tubes).
- A tamibarotene cream was prepared by conventional methods according to the following formulation (data in % by weight) in Table 3.
-
TABLE 3 % by Phase Ingredients INCI name weight A Water Aqua 67.10 Glycerol Glycerin 5.00 Preservatives q.s. B Crodafos CES Cetearyl Alcohol (and) Dicetyl 5.00 Phosphate (and) Ceteth-10 Phosphate Myritol 331 Coco Glyceride 6.00 Tegosoft TN C12-15 Alkyl Benzoate 3.00 Tegosoft DC Decyl Cocoate 3.00 Fitoderme Squalane 2.00 C NaOH solution Sodium Hydroxide q.s. D Dow Corning 345 Cyclomethicone 3.00 Aristoflex AVC Ammonium 0.40 Acryloyldimethyltaurate/ VP Copolymer E EDG Plus Ethoxydiglycol 5.00 Tamibarotene# 0.50 # Adjustments can be made for concentrations - Heat phases A and B separately to 75° C., add phase B to phase A, with stirring, and homogenize, adjust the pH to approx. 5.5-6.5 with phase C, successively add the components of phase D at approx. 65° C. and homogenize. Successively add the components of phase Eat approx. 35° C., cool to room temperature and, if necessary, readjust the pH to 5.0-5.5.
- A study was conducted based upon the following references: OECD 404, Organization for Economic Co-Operation and Development (OECD), Guidelines for the Testing of Chemicals, “Acute Dermal Irritation/Corrosion”, adopted 24 Apr. 2002. ISO 10993-12, 2012, Biological Evaluation of Medical Devices—Part 12: Sample Preparation and Reference Materials. ISO/IEC 17025, 2005, General Requirements for the Competence of Testing and Calibration Laboratories.
- The skin of three albino rabbits was prepared for testing by clipping the skin of the trunk free of hair at the application sites within 24 hours of the test. The sites of application were not abraded deliberately or accidentally during preparation. Tamibarotene was administered at dose levels of 0.02%, 0.04%, and 0.08% in 60% DMSO. The animals were treated by introducing each dose level (0.5 ml) under gauze patches at individual application sites. The control (0.5 ml of 60% DMSO) was applied to a fourth site.
- As it was suspected that tamibarotene might produce severe irritancy/corrosion, a single animal test was initially employed. Test patches of each dose level and control were applied. After three minutes, the skin sites were examined by gently lifting the bandage to examine the skin without bandage removal. Since no serious skin reaction was observed, the sites were examined in the same manner after one hour. The observation at this stage indicated that exposure could humanely be allowed to extend to four hours. If a corrosion effect was observed after three minutes or one hour, the test was to be immediately terminated.
- Because an irritation or corrosive effect was not observed in the initial test after one hour, the response was confirmed using two additional animals dosed with each dose level and control at individual application sites for four hours. At the end of the exposure period, the wrapping was removed from and the skin washed with USP sterile Water for Injection (SWFI) to remove any test substance still remaining. The three animals were observed for signs of erythema and edema at 60 minutes, and then at 24, 48, and 72 hours after bandage removal. Observations were scored according to the Draize Scale for Scoring Skin Reactions.
- All animals gained weight. None of the test sites presented any signs of erythema or edema at any of the observation points. None of the control sites of any animal at any of the observation periods showed signs of erythema or edema.
- The test article was tested for its potential to produce primary dermal irritation after a single topical 4-hour application to the skin of albino rabbits. The test article was considered a non-irritant when tested at dose levels of 0.02%, 0.04%, and 0.08% in 60% DMSO.
- Ammonium lactate is a moisturizing agent known in the art that is typically formulated as an oil in water emulsion for topical administration. Currently available products suffer from the (problem that sufactants used to emulsify sunscreen agents also remove the agents used to promote absorption from the skin when in the presence of water. This causes loss of UV absorbent activity and sun protectant effects sunscreen agents is lost.
- The present invention solves the problem by using a new emulsification technology based on Pemulen. This invention provides novel cosmetic combination compositions of ammonium lactate http://www.drugs.com/ingredient/ammonium-(1), in a novel polymeric emulsification technology using Acrylates/C10-30 Alkyl Acrylate Crosspolymer, (Pemulen™ TR-1 Polymeric Emulsifier). The Acrylates/C10-30 Alkyl Acrylate Crosspolymer, is a versatile polymer which can emulsify up to 30% oil by weight, within a pH range of 4-5.5, and up to 20% oil over the pH range of 3-11. Oil-in-water creams typically at 0.1 percent methyl and propyl parabens are used at levels ranging from 0.01 to 0.3% and fragrance in an ternary sterically stabilized emulsion for topical improvement of skin appearance in normal and aged human skin. Like other oil in water cosmetic emulsions, creams have traditionally been emulsified with stearate or nonionic surfactants at 2%-6%. Inherent to surfactant emulsification of UV absorbers is the propensity for the surfactants to remove the absorbers from the skin when contacted by water.
- Pemulen TR1 is a polymeric emulsifier produced by Noveon. A block copolymer consisting of a poly acrylic acid similar to the Carbopol resins presently used to make aqueous and solvent gels in art conservation (Carbopol 934, Carbopol. 940, Carbopol 941) cross-linked with a long-chained methacrylate, this carbomer has a lipohipllic regions (the methacrylate) as well as hydrophilic regions (the acrylic acid). In the cosmetic industry literature, Pemulen TR-1 is part of a class of copolymers are referred to as acrylate/C10-30 alkyl acrylate cross polymers (6), having the following structure:
- See http://pemulentr2.pbworks.com/f/PemulenTR2.pdf
- These regions of differing affinity allow Pemulen TR1 or TR2 to act as a primary emulsifier, that is, it can be used to make oil in water emulsions without the usual required addition of soap or surfactant.
- Pemulen TR1 or TR2 docs not form emulsions in the same way that traditional surfactants do. To produce oil in water emulsion, a traditional surfactant surrounds a droplet of oil to keep it suspended in oil. Nonionic surfactants used for cleaning painted surfaces, as described in Wolvers' Cleaning Painted Surfaces: Aqueous Methods, might be used in concentrations as high as 30% to form a macroemulsion
- In contrast, Pemulen TR1 is said to form stable O/W emulsions with as little as 0.4%, binding to the oil droplets with the lipophilic portions of the polymer chain that forms the gel.
- Gels made with Pemulen TR-1 are most viscous in the pH range of 5-9. A range of alkaline materials are suggested by the manufacturer to formulate aqueous gels using Pemulen TR-1, including sodium hydroxide, ammonium hydroxide, triethanolamine (TEA), and Ethameen C-25.
- One interesting feature possessed by Pemulen is that this emulsifying agent is designed to break when the gel is in contact with a salt concentration similar to what one would find on human skin. This is a desirable in the cosmetics industry where moisturizers need to be quickly delivered and absorbed into the user's skin, but this may be a less desirable characteristic of an emulsion designed to clean works of art. In practice, this breakage of the emulsion has been observed when attempting to clean very grimy areas and allowing the gel to dwell for an extended period. Although the vast majority of cream or emulsion products in the marketplace contain water-insoluble actives, the surfactants can re-emulsify the actives and cause wash-off, leaving the skin unprotected.
- Those familiar with the art have countered this phenomenon by incorporating waxes or water resistant, film-forming polymers into their formulations. Such a polymer forms an effective barrier, which prevents absorber wash-off, but it may produce negative aesthetic effects such as long rub-in times and a tacky or heavy feel on the skin. However, a novel combination of Ammonium Lactate and Pemulen® polymeric emulsifiers meet the FDA definition of “water-proof” without the use of film-forming polymers, waxes and the like. Because these emulsions contain very little or no surfactants, the water-insoluble UV absorbers remain on the skin, even after an 80 minute exposure to water. The triggered release of the oil phase upon product application ensures that the absorbers are free to spread onto the epidermis where they arc immediately active (1). Ammonium lactate is the ammonium salt of lactic acid. This product specially formulates ammonium lactate 20 wt. percent to provide a cream pH of 4.5-6.5. It may also contain glycerin, isopropyl palmitate, dimethicone, ginko biloba, methyl paraben, propyl paraben or butyl parabens fragrance and water.
- The percentage of Ammonium lactate is preferably between about 17 to about 20 percent. Optionally, the formulation comprises alpha-Bisabolol, an anti-irritant, and/or a retinoid, such as Tamibarotene, or a triterpinoid such as Betulen [473-98-3] C30H50O2, molecular mass 442,7 and related compounds like betulin, lupeol, and betulinic acid.
- The formula is a ternary formulation consisting of three parts which are ultimately combined to form a stable oil in water emulsion. The order of addition of the ingredients should be followed strictly as written in Table 4 and the description that follows. Otherwise, the ingredients fall out of solution.
-
TABLE 4 Ingredient Percent Weight (g) Ternary Ingredient-Part 1 Order of Addition Demineralized Water 63.1 155.5 Methyl Paraben 0.1 0.5 Propyl Paraben 0.1 0.5 Glycerin 2.0 10.0 Ammonium Lactate (20 wt. %) 8.0 200.0 Total 73.3 366.5 Ternary Ingredient-Part 2 Order of Addition Demineralized Water 18.0 90.0 Isopropyl Palmitate 2.5 12.5 Dimethicone (Mw 30,000) 2.5 12.5 White Petrolatum 1.0 5.0 Ginkgo (Ginkgo biloba) 1.0 5.0 Total 25.0 125.0 Ternary Ingredients-Part 3 Order of Addition Pemulen ® TR 1.5 7.5 Fragrance (Belle Air #7564) 0.2 1.0 Total 1.7 8.5 Total all 3 parts 100.0 500.0 - Part 1 is formed as follows:
- a. Add Demineralized water to a 1000 ml beaker. Stirring or Agitation at 600 rpm
- b. Add methyl paraben
- c. Add propyl paraben
- d. Add glycerin
- e. Add ammonium Lactate
- f. Increase stirring rate or agitation to 1500 rpm
- Part 2 is formed as follows:
- i. Add demineralized water to an 800 ml beaker. Stir or Agitation at 600 rpm
- ii. Add Isopropyl palmitate
- iii. Add dimethicone
- iv. Add white petrolatum
- v. Add gingko biloba
- vi. Increase agitation or stirring 1500 rpm
- Mix part 1 and part 2 for 30 minutes
- a. Slow agitation or stirring down on part 1 to 600 rpm and blend part 2 into part 1
- b. Increase agitation of the combined formulation to 1800 rpm for 30 minutes
c. Part 3 - The final formulation is produced as follows:
- a. Slow agitation of combined formulation to 600 rpm
- b. Add Pemulen® TR1 OR TR2 very slowly (all of it)
- c. Increase stirring speed to 1800 rpm for 30 minutes to disperse all of Pemulen® TR1 OR TR2
- d. Increase agitation to 2800 rpm and hold until the emulsion is smooth and creamy without any of the oils floating on the surface
- e. Slow agitation down to 600 rpm and add the fragrance
- f. Mix well and place in a proper container (jar or tubes)
- A combination tamibarotene and ammonium lactate anti-wrinkle emulsion can be prepared as shown below.
-
TABLE 5 Ingredient Percent Weight (g) Ternary Ingredient-Part 1 Order of Addition 1. Demineralized Water 63.1 155.5 2. Methyl Paraben 0.1 0.5 3. Propyl Paraben 0.1 0.5 4. Glycerin 1.0 10.0 5. Ammonium Lactate (20 wt. %) 8.0 200.0 6. Tamibarotene (suspended in 0.05-1.0 1.8-3.51 Ammonium Lactate §Total (adjusted according to 73.3 370.0 Active Concentrations) Ternary Ingredient-Part 2 Order of Addition 1. Demineralized Water 18.0 90.0 2. Isopropyl Palmitate 2.5 12.5 3. Dimethicone (Mw 30,000) 2.5 12.5 4. White Petrolatum 1.0 5.0 5. Ginkgo (Ginkgo biloba) 1.0 5.0 Total 25.0 125.0 Ternary Ingredients-Part 3 Order of Addition 1. Pemulen ® TR 1.5 7.5 2. Fragrance (Belle Air #7564) 0.2 1.0 3. Total 1.7 8.5 Total all 3 parts 100.0 500.0 - A. Part 1.
- The order of addition of the ingredients is listed just the way the formulation is written (through all stages). Otherwise, the ingredients fall out of solution.
- a. Add Demineralized water to a 1000 ml beaker. Stirring or Agitation at 600 rpm
- b. Add methyl paraben
- c. Add propyl paraben
- d. Add glycerin
- e. Add ammonium Lactate
- f. Increase stirring rate or agitation to 1500 rpm
- B. Part 2
- a. Add demineralized water to an 800 ml beaker. Stir or Agitation at 600 rpm
- b. Add Isopropyl palmitate
- c. Add dimethicone
- d. Add white petrolatum
- e. Add gingko biloba
- f. Increase agitation or stirring 1500 rpm
- C. Mix part 1 and part 2 for 30 minutes.
- D. Slow agitation or stirring down on part 1 to 600 rpm and blend part 2 into part 1.
- E. Increase agitation of the combined formulation to 1800 rpm for 30 minutes.
- F. Part 3
-
- 1. Slow agitation of combined formulation to 600 rpm
- 2. Add Pemulen® TR1 OR TR2 very slowly (all of it)
- 3. Increase stirring speed to 1800 rpm for 30 minutes to disperse all of Pemulen® TR1 OR TR2
- 4. Increase agitation to 2800 rpm and hold until the emulsion is smooth and creamy without any of the oils floating on the surface.
- 5. Slow agitation down to 600 rpm and add the fragrance
- 6. Mix well and place in a proper container (jar or tubes).
- One of skill in the art will appreciate that substitutions and deviations from the above formulation may be permissible without departing from the spirit of the invention as long as the changes to not break the emulsion. In particular the use of tinting agents and perfumes arc contemplated.
-
-
- 1. http://www.drugs.com/ingredient/ammouium-lactate.html{http:/pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10586}
- 2. http://www.lubrizol.com/PersonalCare/Products/Pemulen/PemulenTR-1.html
- 3. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=1201551&loc=cc_rcs
- 4. Y. Hamada. I. Yamada. M. Uenaka, T. Sakata, U.S. Pat. No. 5,214,202 (1993).
- In one aspect of the invention, is a composition for reducing the effects of aging comprising tamibarotene in a cosmetically acceptable carrier. In one embodiment, the effects of aging are selected from increase in skin roughness, loss of skin elasticity, increase in skin transparency, skin fragility, increased frequency of bruising, macroscopic appearance of skin wrinkles and folds, and skin discoloration. In one embodiment, the carrier is at least one polyethylene glycol (PEG) of cosmetically acceptable grade. In one embodiment, the polyethylene glycol is a mixture of PEG 300 and PEG 1540. In another embodiment, the tamibarotene is dissolved in PEG 300 and added to melted PEG 1540. In one embodiment, the composition further comprises an anti-irritant. In one embodiment, the anti-irritant is (-)-α-Bisabolol. In another embodiment, the composition comprises an antioxidant. In one embodiment, the anti-oxidant is butylated hydroxytoluene (BHT). In another embodiment, the composition is stable at room temperature.
- In another aspect of the invention is a topical formulation of tamibarotene co-formulated with ammonium lactate in an acrylates/C10-30 alkyl acrylate crosspolymer. In one embodiment, the topical formulation is a formulation that is a sterically stabilized oil in water (o/w) emulsion. In another embodiment, the ammonium lactate is present from about 17 to about 20 percent by weight, in another embodiment, the composition further comprises an anti-irritant and/or a retinoid. In one embodiment, the anti-irritant is (-)-α-Bisabolol.
- In another aspect of the invention is a ternary formulation of tamibarotene comprising:
-
- a. a first part comprising tamibarotene dissolved in at least one paraben, water, and glycerin;
- b. a second part comprising water, an emollient, a siloxane, and petrolatum; and
- c. a third part comprising the first and second parts together with an acrylates/C10-30 alkyl acrylate crosspolymer.
- In one embodiment, the ternary formulation comprises an additional cosmetic agent.
- In another embodiment, the ternary formulation is a formulation in which:
-
- a. the first part comprises demineralized water, methyl paraben, propyl paraben, glycerin, and tamibarotene;
- b. the second part comprises demineralized water, isopropyl palmitate, dimethicone, white petrolatum, gingko biloba; and
- c. the third part comprises parts one and two together with Pemulen™.
- In another aspect of the invention is a method of making a ternary formulation of tamibarotene comprising:
-
- a. forming a first part:
- i. adding demineralized water to a 1000 ml beaker;
- ii. stirring or agitation at 600 rpm;
- iii. adding methyl paraben;
- iv. adding propyl paraben;
- v. adding glycerin;
- vi. adding tamibarotene;
- vii. increasing stirring rate or agitation to 1500 rpm;
- b. forming a second part by:
- i. adding demineralized water to an 800 ml beaker;
- ii. stirring or agitating at 600 rpm;
- iii. adding isopropyl palmitate;
- iv. adding dimethicone;
- v. adding white petrolatum;
- vi. adding gingko biloba:
- vii. increasing agitation or stirring to 1500;
- viii. mix part 1 and part 2 for 30 minutes;
- 1. slow agitation or stirring down on part 1 to 600 rpm and blend part 2 into part 1;
- 2. increase agitation of the combined formulation to 1800 rpm for 30 minutes:
- c. forming a third part by:
- i. slow agitation of combined formulation of the second part to 600 rpm;
- ii. adding Pemulen™ TR-1 or TR-2 very slowly;
- iii. increasing stirring speed to 1800 rpm for 30 minutes to disperse all of Pemulen™® TR-1 or TR-2;
- iv. increasing agitation to 2800 rpm and until the emulsion is smooth and creamy without any of the oils floating on the surface;
- v. slowing agitation down to 600 rpm and adding a fragrance; and
- vi. mixing well and placing in a proper vessel.
- a. forming a first part:
- In another embodiment is a topical formulation of ammonium lactate in an acrylates/C10-30 alkyl acrylate crosspolymer. In one embodiment, the formulation is an oil in water (o/w) emulsion. In one embodiment of the topical formulation, the ammonium lactate is present from about 17 to about 20 percent by weight. In another embodiment, the topical formulation comprises an anti-irritant, and or a retinoid. In one embodiment, the anti-irritant is (-)-α-Bisabolol and the retinoid is tamibarotene.
- In another embodiment is a method of making a ternary formulation of ammonium lactate comprising:
-
- a. forming a first part by:
- i. adding demineralized water to a 1000 ml beaker;
- ii. stirring or agitating at 600 rpm;
- iii. adding methyl paraben;
- iv. adding propyl paraben:
- v. adding glycerin;
- vi. adding ammonium lactate.
- vii. increasing stirring rate or agitating to 1500 rpm: forming a second part:
- i. adding demineralized water to an 800 ml beaker;
- ii. stirring or agitating at 600 rpm;
- iii. adding isopropyl palmitate;
- iv. adding dimethicone;
- v. adding white petrolatum;
- vi. adding gingko biloba;
- vii. increasing stirring rate or agitating to 1500 rpm;
- viii. mixing part 1 and part 2 for 30 minutes;
- ix. slowly agitating or stirring down part 1 to 600 rpm and blend part 2 into part 1;
- x. increasing the agitation or the stirring rate of the combined formulation to 1800 rpm for 30 minutes;
- c. forming a third part by:
- i. slow agitation or stirring of combined formulation of the second part to 600 rpm;
- ii. adding Pemulen™® TR-1 or TR-2 very slowly (all of it);
- iii. increasing stirring rate to 1800 rpm for 30 minutes to disperse all of Pemulen™® TR-1 or TR-2;
- iv. increasing agitation to 2800 rpm and hold until the emulsion is smooth and creamy without any of the oils floating on the surface;
- v. slowing agitation down to 600 rpm and adding fragrance; and
- vi. mixing well and placing in a proper container (jar or tubes).
- a. forming a first part by:
Claims (43)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/143,428 US20210308026A1 (en) | 2013-03-15 | 2021-01-07 | Topical compositions for reducing the effects of aging |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361789701P | 2013-03-15 | 2013-03-15 | |
US201361790370P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/030033 WO2014145295A1 (en) | 2013-03-15 | 2014-03-15 | Topical compositions for reducing aging effects |
US201514775920A | 2015-09-14 | 2015-09-14 | |
US16/380,808 US11039995B2 (en) | 2013-03-15 | 2019-04-10 | Topical compositions for reducing the effects of aging |
US17/143,428 US20210308026A1 (en) | 2013-03-15 | 2021-01-07 | Topical compositions for reducing the effects of aging |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/380,808 Continuation US11039995B2 (en) | 2013-03-15 | 2019-04-10 | Topical compositions for reducing the effects of aging |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210308026A1 true US20210308026A1 (en) | 2021-10-07 |
Family
ID=51537940
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/775,920 Granted US20160000674A1 (en) | 2013-03-15 | 2014-03-15 | Topical compositions for reducing the effects of aging |
US16/380,808 Active 2034-07-02 US11039995B2 (en) | 2013-03-15 | 2019-04-10 | Topical compositions for reducing the effects of aging |
US17/143,428 Abandoned US20210308026A1 (en) | 2013-03-15 | 2021-01-07 | Topical compositions for reducing the effects of aging |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/775,920 Granted US20160000674A1 (en) | 2013-03-15 | 2014-03-15 | Topical compositions for reducing the effects of aging |
US16/380,808 Active 2034-07-02 US11039995B2 (en) | 2013-03-15 | 2019-04-10 | Topical compositions for reducing the effects of aging |
Country Status (5)
Country | Link |
---|---|
US (3) | US20160000674A1 (en) |
EP (1) | EP2969031A4 (en) |
JP (1) | JP2016518342A (en) |
CA (1) | CA2906800A1 (en) |
WO (1) | WO2014145295A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160000674A1 (en) | 2013-03-15 | 2016-01-07 | Avisenna Cosmetics, Llc | Topical compositions for reducing the effects of aging |
CA3059291A1 (en) * | 2017-04-06 | 2018-10-11 | Derm-Biome Pharmaceuticals Inc. | Compositions and methods for treatment of infection and novel cosmeceutical preparations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020022040A1 (en) * | 2000-07-10 | 2002-02-21 | The Proctor & Gamble Company | Methods of enhancing delivery of oil-soluble skin care actives |
US6551605B2 (en) * | 2001-04-06 | 2003-04-22 | Haarmann & Reimer | Diesters or polyesters of naphthalene dicarboxylic acid as solubilizer/stabilizer for retinoids |
US20100048708A1 (en) * | 2007-03-30 | 2010-02-25 | Hisao Ekimoto | Tamibarotene capsule preparation |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663850B1 (en) * | 1990-07-02 | 1994-01-14 | Gird Galderma | PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A RETINOUIDE AND A STEROL IN COMBINATION. |
US6080393A (en) * | 1994-07-09 | 2000-06-27 | Johnson & Johnson Consumer Products, Inc. | Skin care composition comprising a retinoid |
JP3681200B2 (en) * | 1994-09-07 | 2005-08-10 | ジョンソン・エンド・ジョンソン株式会社 | Container for skin care composition |
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
ES2349461T3 (en) | 2000-09-01 | 2011-01-03 | Toko Pharmaceutical Ind. Co. Ltd | CRYSTAL PRODUCTION PROCEDURE OF A BENZOIC ACID DERIVATIVE. |
ZA200408744B (en) | 2002-04-22 | 2005-11-10 | Res Found Itsuu Lab | Drugs for treating vascular diseases. |
JP2005020400A (en) | 2003-06-26 | 2005-01-20 | Hitachi Communication Technologies Ltd | Radio base station, radio communication system, communication control method of radio base station, and construction method of radio communication network |
CA2513586A1 (en) | 2003-01-17 | 2004-08-05 | Wisconsin Alumni Research Foundation | Method of reducing toxicity of retinoids |
US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
AU2005210668A1 (en) * | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
US20050202055A1 (en) * | 2004-03-11 | 2005-09-15 | Koichi Shudo, Tokyo, Japan | Anti-wrinkle agent |
EP1930001A4 (en) | 2005-09-09 | 2010-07-21 | Kemphys Ltd | Pharmaceutical for use in prevention and/or treatment of bowel disease |
US20090281184A1 (en) | 2005-09-27 | 2009-11-12 | Sapporo Medical University | Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability |
JP2008081427A (en) | 2006-09-27 | 2008-04-10 | R&R Inc | Medicine for prevention and/or treatment of deficient secretion disease |
WO2009151914A1 (en) * | 2008-05-27 | 2009-12-17 | Smithkline Beecham Corporation | Methods for treating neoplasms with a combination of a plk inhibitor and retinoid |
KR102083046B1 (en) | 2012-06-07 | 2020-02-28 | 칠드런'스 하스피틀 로스 앤젤레스 | Methods for treating neutropenia using retinoid agonists |
CN102961346A (en) | 2012-12-19 | 2013-03-13 | 山东大学 | Tamibarotene nano-liposome carrier and preparation method thereof |
US20160000674A1 (en) | 2013-03-15 | 2016-01-07 | Avisenna Cosmetics, Llc | Topical compositions for reducing the effects of aging |
AU2015262349A1 (en) | 2014-05-21 | 2017-02-02 | National Institute Of Advanced Industrial Science And Technology | Cancer stem cell proliferation inhibitor |
CA2962540A1 (en) | 2014-09-25 | 2016-03-31 | Manu Chaudhary | Stealth, targeted nanoparticles (stn) for oral drug delivery |
ES2901792T3 (en) | 2015-03-31 | 2022-03-23 | Syros Pharmaceuticals Inc | Patient Stratification Procedures for Retinoic Acid Receptor Agonist Treatment |
US10940127B2 (en) | 2015-11-25 | 2021-03-09 | Io Therapeutics, Inc. | Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
WO2018045289A1 (en) | 2016-09-02 | 2018-03-08 | Zon Leonard I | Methods for treatment of adenoid cystic carcinoma |
JP2019043865A (en) | 2017-08-31 | 2019-03-22 | ひまわり製薬株式会社 | Skin external composition for treating or preventing acne-like disease |
EP3479845A1 (en) | 2017-11-06 | 2019-05-08 | Stalicla S.A. | Challenge test for diagnosing subtype of autism spectrum disease |
EP3752159A4 (en) | 2018-02-13 | 2021-11-24 | Transgenex Nanobiotech, Inc. | Novel crystalline forms of tamibarotene for treatment of cancer |
-
2014
- 2014-03-15 US US14/775,920 patent/US20160000674A1/en active Granted
- 2014-03-15 CA CA2906800A patent/CA2906800A1/en active Pending
- 2014-03-15 EP EP14764495.9A patent/EP2969031A4/en not_active Withdrawn
- 2014-03-15 JP JP2016503312A patent/JP2016518342A/en active Pending
- 2014-03-15 WO PCT/US2014/030033 patent/WO2014145295A1/en active Application Filing
-
2019
- 2019-04-10 US US16/380,808 patent/US11039995B2/en active Active
-
2021
- 2021-01-07 US US17/143,428 patent/US20210308026A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020022040A1 (en) * | 2000-07-10 | 2002-02-21 | The Proctor & Gamble Company | Methods of enhancing delivery of oil-soluble skin care actives |
US6551605B2 (en) * | 2001-04-06 | 2003-04-22 | Haarmann & Reimer | Diesters or polyesters of naphthalene dicarboxylic acid as solubilizer/stabilizer for retinoids |
US20100048708A1 (en) * | 2007-03-30 | 2010-02-25 | Hisao Ekimoto | Tamibarotene capsule preparation |
Also Published As
Publication number | Publication date |
---|---|
US20160000674A1 (en) | 2016-01-07 |
EP2969031A1 (en) | 2016-01-20 |
EP2969031A4 (en) | 2017-03-08 |
US20190298629A1 (en) | 2019-10-03 |
WO2014145295A1 (en) | 2014-09-18 |
CA2906800A1 (en) | 2014-09-18 |
JP2016518342A (en) | 2016-06-23 |
US11039995B2 (en) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8568704B2 (en) | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer | |
TW508246B (en) | Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions | |
US8128947B2 (en) | Surfactant-free dispersions, compositions, and use in topical formulations | |
JP2011126879A (en) | Mild leave-on skin care composition | |
US20100247693A1 (en) | Cosmetic formulation to treat rosacea telangiectasia | |
US8709392B2 (en) | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | |
WO2009129627A1 (en) | Novel resveratrol compositions | |
US20210308026A1 (en) | Topical compositions for reducing the effects of aging | |
KR20190137781A (en) | Topical Formulations and Methods | |
JP2005162728A (en) | Mupirocin composition for local use, improved process for producing the same and method for using the same | |
WO2009042402A2 (en) | Composition and method for treating rosacea | |
US20040191206A1 (en) | Methods for reduction of inflammation and erythema | |
US11400071B2 (en) | Hest G-18-0 and benzoyl peroxide compositions and methods for using the same | |
EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
US20210023000A1 (en) | Topical compositions | |
WO2024012385A1 (en) | Composition comprising artemisiae annuae herba extract and functional active substance and use thereof | |
MX2011009514A (en) | A cosmetic composition for skin lightening. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SAMSON PHARMA, LLC, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVISENNA COSMETICS, LLC;REEL/FRAME:059092/0041 Effective date: 20190717 Owner name: AVISENNA COSMETICS, LLC, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DURRANI, MANZER J.;REEL/FRAME:059091/0979 Effective date: 20150911 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |